Francis Adu-Amankwaah

Francis Adu-Amankwaah

Auto-generated profile, based on publicly available information

Francis Adu-Amankwaah

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Heliyon
Verified
Journal Article
Open access
KTKudzanai Ian Tapfuma
Kudzanai Ian Tapfuma
KNKudakwashe Nyambo
Kudakwashe Nyambo
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
LBLucinda Baatjies
Lucinda Baatjies
LSLiezel Smith
Liezel Smith
Vuyo MavumengwanaVuyo Mavumengwana
Vuyo Mavumengwana
The number and diversity of drugs in the tuberculosis (TB) drug development process has increased over the years, yet the attrition rate remains very high, signaling the need for continued research in drug discovery. In this study, crude secondary metabolites from marine fungi associated with ascidians collected from Saldanha and False Bays (South Africa) were investigated for antimycobacterial activity. Isolation of fungi was performed by sectioning thin inner-tissues of ascidians and spreading them over potato dextrose agar (PDA). Solid state fermentation of fungal isolates on PDA was then performed for 28 days to allow production of secondary metabolites. Afterwards, PDA cultures were dried and solid-liquid extraction using methanol was performed to extract fungal metabolites. Profiling of metabolites was performed using untargeted liquid chromatography quadrupole time-of-flight tandem mass spectrometry (LC-QTOF-MS/MS). The broth microdilution method was used to determine antimycobacterial activity against Mycobacterium smegmatis mc2155 and Mycobacterium tuberculosis H37Rv, while in silico flexible docking was performed on selected target proteins from M. tuberculosis. A total of 16 ascidians were sampled and 46 fungi were isolated. Only 32 fungal isolates were sequenced, and their sequences submitted to GenBank to obtain accession numbers. Metabolite profiling of 6 selected fungal extracts resulted in the identification of 65 metabolites. The most interesting extract was that of Clonostachys rogersoniana MGK33 which inhibited Mycobacterium smegmatis mc2155 and Mycobacterium tuberculosis H37Rv growth with minimum inhibitory concentrations (MICs) of 0.125 and 0.2 mg/mL, respectively. These results were in accordance with those from in silico molecular docking studies which showed that bionectin F produced by C. rogersoniana MGK33 is a potential inhibitor of M. tuberculosis β-ketoacyl-acyl carrier protein reductase (MabA, PDB ID = 1UZN), with the docking score observed as −11.17 kcal/mol. These findings provided evidence to conclude that metabolites from marine-derived fungi are potential sources of bioactive metabolites with antimycobacterial activity. Even though in silico studies showed that bionectin F is a potent inhibitor of an essential enzyme, MabA, the results should be validated by performing purification of bionectin F from C. rogersoniana MGK33 and in vitro assays against MabA and whole cells (M. tuberculosis).

25 August 2022 in South African Journal of Botany
Verified
Journal Article
Open access
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
KTKudzanai Ian Tapfuma
Kudzanai Ian Tapfuma
RHRaeesa Hoosen Hussan
Raeesa Hoosen Hussan
NTNdivhuwo Tshililo
Ndivhuwo Tshililo
LBLucinda Baatjies
Lucinda Baatjies
Vuyo MavumengwanaVuyo Mavumengwana
Vuyo Mavumengwana

29 November 2024 in Phytomedicine Plus
Verified
Journal Article
Open access
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
HMHleziphi V. Mpundu
Hleziphi V. Mpundu
KNKudakwashe Nyambo
Kudakwashe Nyambo
PSPaula Strauss
Paula Strauss
KTKudzanai Ian Tapfuma
Kudzanai Ian Tapfuma
LBLucinda Baatjies
Lucinda Baatjies

21 June 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
HSHephzibah Sam
Hephzibah Sam
CAChris Yaw Asare
Chris Yaw Asare
FMFelix Charles Mills-Robertson
Felix Charles Mills-Robertson
The death of many people in tropical countries can be attributed to microbial infection, probably, because synthetic antibiotics are failing in the treatment of most microbial infections, attributed to the ability of the microorganisms to mutate and adapt to harsh conditions. This study evaluated, in vitro, the antimicrobial activities, antioxidant potentials, and the total phenolic as well as phytochemical contents of aqueous and ethanol extracts of the root of Cryptolepis sanguinolenta (Lindl.) and the crude sap of Pycnanthus angolensis (Welw) using selected standard bacteria strains (Staphylococcus aureus (ATCC 25,923), Staphylococcus saprophyticus (ATCC 15,305), Escherichia coli (ATCC 25,922), Salmonella typhi (ATCC 19,430), Pseudomonas aeruginosa (ATCC 27,853), and Proteus mirabilis (ATCC 49,565). The modified agar well diffusion method was used to evaluate the antimicrobial activities of the plant extracts. Chloramphenicol and tetracycline were used as positive controls. The extracts were screened for specific phytochemicals with total phenolic contents were determined using Folin Ciocalteu reagent test. The phytoconstituents observed were alkaloids, cardiac glycosides, and saponins in both Cryptolepis sanguinolenta and Pycnanthus angolensis. For the antimicrobial activities, all the test bacteria were susceptible to the crude sap of Pycnanthus angolensis except Proteus mirabilis. In the case of the Cryptolepis sanguinolenta, only S. aureus was susceptible to both aqueous and ethanol extracts. The total phenolic content, expressed in g/100 g GAE, recorded values of 55.427 ± 4.248 for the crude sap of Pycnanthus angolensis, and 11.642 ± 4.248 and 26.888 ± 4.248 for the aqueous and ethanol extracts of Cryptolepis sanguinolenta, respectively. It is concluded that Cryptolepis sanguinolenta and Pycnanthus angolensis are excellent candidates for further development of antimicrobial agents in the fight against microbial infections given the pressing need for novel efficacious agents.

17 January 2025 in South African Journal of Botany
Verified
Journal Article
Open access
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
KTKudzanai Ian Tapfuma
Kudzanai Ian Tapfuma
KNKudakwashe Nyambo
Kudakwashe Nyambo
GMGerald Maarman
Gerald Maarman
Brian SM MunansanguBrian SM Munansangu
Brian SM Munansangu
LBLucinda Baatjies
Lucinda Baatjies

5 October 2025 in Cytokine
Verified
Journal Article
Open access
EMEwura-Esi Manful
Ewura-Esi Manful
FAFrancis Adu-Amankwaah
Francis Adu-Amankwaah
AMAbhilasha Madhvi
Abhilasha Madhvi
KBKayla Bubb
Kayla Bubb
RPRay-Dean Pietersen
Ray-Dean Pietersen
BBBienyameen Baker
Bienyameen Baker
The interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) is a crucial member of the interferon-stimulated gene (ISG) family, widely acknowledged for its antiviral activity. IFIT2 functions primarily through AU-rich RNA binding, aiding in viral suppression by inhibiting protein translation and promoting apoptosis via mitochondrial pathways. While traditionally known for its role in antiviral defence, emerging research highlights its broader significance in cancer, bacterial and fungal infections, autoimmune diseases, neurological disorders, and metabolic and cardiovascular conditions. Notably, IFIT2 is the only IFIT family member with established tumour suppressor properties, demonstrating anti-proliferative effects in multiple cancers, including lung, renal, colorectal, breast, and gallbladder cancers. Beyond oncology, IFIT2 has been implicated in the host response to Mycobacterium tuberculosis, Plasmodium spp., Candida albicans, and Treponema pallidum, where it modulates immune responses and infection outcomes. It is upregulated in several autoimmune diseases such as systemic lupus erythematosus, Sjögren's syndrome, and multiple sclerosis, suggesting its potential as a diagnostic and therapeutic biomarker. Furthermore, transcriptomic analyses have linked IFIT2 to disease progression and treatment response in conditions like diabetic ulcers, gestational diabetes, ischaemic cardiomyopathy, schizophrenia, and Alzheimer's disease. This review thoroughly examines the molecular structure, regulatory mechanisms, and diverse roles of IFIT2 in human diseases. It addresses its interaction with key immune pathways, its ability to modulate apoptosis and inflammation, and its potential as a prognostic marker and therapeutic target. Although its mechanistic functions in numerous diseases remain only partly understood, IFIT2 emerges as a versatile immune effector with considerable translational promise. Further investigation into its biological roles will be crucial for utilising its therapeutic potential across infectious, inflammatory, metabolic, and neoplastic diseases.